ATP敏感性钾通道开放剂埃他卡林对高原脱习服的影响

目的：观察长期口服埃他卡林对高原脱习服的影响。方法：该临床研究采用随机双盲安慰剂平行对照试验方法，随机分为埃他卡林试验组和安慰剂对照组，两组受试者分别为39例和17例。其中，受试者分别口服埃他卡林片（5mg／片，1次／日）或安慰剂（1片／日），连续服用药物7个月，下山到3700m停留2d并停止服药，再返回到海拔1400m的平原地区，自返回平原的第2、4、6天，进行高原脱习服症状调查，随访受试者的高原脱习服症状并进行症状评分。结果：长期驻扎在5200～5380m高海拔地区的受试者，返回平原后第2、4、6天，分别有82．4％、52．9％、23．5％的人员产生显著的高原脱习服症状，长期口服埃他卡林，高原脱习服发生率分别为43．6％、30．8％、38．5％；安慰剂对照组返回平原后脱习服反应程度的评分，在第2、4、6天分别为（6．0±1．9）、（4．6土1．0）、（3．8±1．5）分，埃他卡林治疗组分别为（4．4±2．4）、（3．3±1．8）、（4．0±1．5）分，两组比较，在返回低海拔第2、4天，高原脱习服反应的发病率及发病程度均显著减少，第6天的数据两组之间差别无统计学意义。结论：高原地区长期口服埃他卡林可显著减轻高原脱习服的发病程度，降低高原脱习服的发生率，预防高原脱习服。

Effects of ATP-sensitive potassium channel opner iptakalim on deacclimatization to high altitude

To study the effects of iptakalim, a novel ATP-sensitive potassium channel opner, against deacclimatization to high altitude. METHODS: This study was performed with a randomized, double-blind, placebo-controlled, parallel-group design. Fifty-six male soldiers were randomly divided into two groups: treatment group (39 men) and control group (17 men). The subjects were taken iptakalim tablets (5 mg/tablet, once a day) or placebo (once a day) respectively,for 7 months. The treatment was stopped at the 2 days before the subjects return to 3400 m altitude, and then returned to plain (1400 m). The questionnaire of symptoms of deacclimatization to high altitude was used on the 2nd, 4th, 6th day after the subjects returned to 1400 m altitude and the scores of deacclimatization symptoms were evaluated. RESULTS: A-mong the 17 men staying at 5200 - 5380 m high altitude for a long time, the incidences of deacclimatization to high altitude were 82.4%, 52. 9% and 23. 5% on the 2nd, 4th, 6th day after they returned to 1400 m altitude,respectively. After treated with iptakalim for 7 months, the incidences of deacclimatization were 43. 6 %,30.8% and 38. 5% , respectively. The scores of deacclimatization symptoms of placebo-control group on the 2nd and 4th,6th day after returning to 1400 m were 6.0±1.9, 4.6 + 1.0 and 3. 8± 1.5 respectively, while those in iptakalim-trea-ted group were 4. 4 + 2. 4, 3. 3 ± 1. 8 and 4. 0 ± 1. 5 respectively. Compared with control, symptoms of deacclimatization to high altitude of treatment group were reduced significantly on the 2nd and 4th day after returning to 1400 m. There was no statistically significant difference in scores of deacclimatization symptoms between the two groups on the 6th day. CONCLUSION: Iptakalim can decrease the incidence of deacclimatization to high altitude, mitigate the symptoms of deacclimatization to high altitude. Iptakalim have a significant effect on prevention and treatment of deacclimatization to high altitude.